Medical Oncology

, Volume 17, Issue 1, pp 35–38 | Cite as

Seropositivity for MIA and S100 in patients with gastrointestinal carcinomas

Original Paper


Serum levels of melanoma inhibiting activity (MIA) and S100, both markers in malignant melanoma, are increased only in few patients with non-melanocytic tumors. We examined a series of serum samples from patients with colorectal (CRC) (N=56), gastric (GC) (N=43), pancreatic (PC) (N=29), hepatocellular (HCC) (N=30), cholangiocellular and gallbladder carcinoma (CCC) (N=18). MIA and S100 were measured by commercially available assays. Positive serum levels for MIA and S100 were found in 16.1% and 5.4% of the patients with CRC, 11.6% and 9.3% with GC, 34.5% and 13.8% with PC,0% and 30% with HCC and 16.7% with CCC, respectively. All patients with sera positive for either MIA or S100 suffered from advanced tumors and received palliative treatment. Elevated serum levels of MIA and S100 are frequentin patients with gastrointestinal cancer. Further investigation is warranted to define the role of MIA or S100 seropositivity in gastrointestinal cancer with regard to follow-up.


melanoma inhibiting activity S100 tumor marker ELISA gastrointestinal carcinomas 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Guo HBet al. Clinical significance of serum S100 in metastatic malignant melanoma.Eur J Cancer 1995;31A: 1898–1902.PubMedCrossRefGoogle Scholar
  2. 2.
    Bosserhoff AKet al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.Cancer Res 1997;57: 3149–3153.PubMedGoogle Scholar
  3. 3.
    Miliotes Get al. Evaluation of new putative tumor markers for melanoma.Ann Surg Oncol 1996;3: 558–563.PubMedCrossRefGoogle Scholar
  4. 4.
    Von Schoultz Eet al. Prognostic value of serum analyses of S100b protein in malignant melanoma.Melanoma Res 1996;6: 133–137.CrossRefGoogle Scholar
  5. 5.
    Deichmann Met al. S100β, MIA and LDH discriminate progressive from non-progressive AJCC stage IV melanoma disease.J Clin Oncol 1999; accepted for publication.Google Scholar
  6. 6.
    Dietz U, Sandell LJ. Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis.J Biol Chem 1996;271: 3311–3316.PubMedCrossRefGoogle Scholar
  7. 7.
    Isobe T, Ishioka N, Okuyama T. Structural relation of two S-100 proteins in bovine brain; subunit composition of S-100a protein.Eur J Biochem 1981;115: 469–474.PubMedCrossRefGoogle Scholar
  8. 8.
    Isobe T, Takahashi K, Okuyama T. S-100a protein is present in neurons of central and peripheral nervous system.J Neurochem 1984;43: 1494–1496.PubMedCrossRefGoogle Scholar
  9. 9.
    Nakajima T, Sato Y, Watanabe S, Sakurai M, Hidaka H. Immunoelectron microscopical demonstration of S100 protein in epidermal Langerhans cells.Biomed Res 1982;8: 226–231.Google Scholar
  10. 10.
    Stefansson K, Wollman R, Jerkovic M. S100 protein in tissue tumors derived from Schwann cells and melanocytes.Pathology 1982;106: 261–268.Google Scholar
  11. 11.
    Hidaka Het al. Purification and characterization of adipose tissue S100b protein.J Biol Chem 1985;258: 2705–2709.Google Scholar
  12. 12.
    Kato K, Kimura S. S100a protein is mainly located in the heart and striated muscles.Biochim Biophys Acta 1985;842: 146–150.PubMedGoogle Scholar
  13. 13.
    Semba R, Kato K, Isobe T, Kashiwamata S. Purification of S100a protein from rat kidney.Brain Res 1987;401: 9–13.PubMedCrossRefGoogle Scholar
  14. 14.
    Mokuno Ket al. Neuron-specific enolase and S-100 protein levels in cerebrospinal fluid of patients with various neurological diseases.J Neurol Sci 1983;60: 443–451.PubMedCrossRefGoogle Scholar
  15. 15.
    Persson Let al. S-100 protein and neuronspecific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system.Stroke 1987;18: 911–918.PubMedGoogle Scholar
  16. 16.
    Fagnart O, Sindic C, Laterre C. Particle counting immunoassay of S-100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system.Clin Chem 1988;34: 1387–1391.PubMedGoogle Scholar
  17. 17.
    Aurell A, Rosengren LE, Wikkelsö C, Nordberg G, Haglid KG. The S-100 protein in cerebrospinal fluid: a simple ELISA method.J Neurol Sci 1989;89: 157–164.PubMedCrossRefGoogle Scholar
  18. 18.
    Aurell Aet al. Determination of S-100 and GFA protein concentrations in cerebrospinal fluid after brain infarction.Stroke 1991;22: 1254–1258.PubMedGoogle Scholar
  19. 19.
    Hardemark HGet al. S-100 protein and neuronspecific enolase in CSF after experimental traumatic or focal ischemic brain damage.J Neurosurg 1989;71: 727–731.PubMedGoogle Scholar
  20. 20.
    Ingebrigtsen T, Romner B, Kongstad P, Langbakk B. Increased serum concentrations of protein S-100 after minor head injury: a biochemical serum marker with prognostic value?J Neurol Neurosurg Psychiatry 1995;59: 103–104.PubMedCrossRefGoogle Scholar
  21. 21.
    Johnsson Pet al. Cerebral complications after cardiac surgery assessed by S-100 and NSE levels in blood.J Cardiothorac Vasc Anesth 1995;9: 1–7.CrossRefGoogle Scholar
  22. 22.
    Gaynor Ret al. S100 protein: a marker for human malignant melanomas?Lancet 1981;1: 869–871.PubMedCrossRefGoogle Scholar
  23. 23.
    Drier JK, Swanson PE, Cherwitz DL, Wick MR. S100 protein immuno-reactivity in poorly differentiated carcinomas. Immunohistochemical comparison with malignant melanoma.Arch Pathol Lab Med 1987;111: 447–452.PubMedGoogle Scholar
  24. 24.
    Hancock C, Allen BC, Herrera GA. HMB-45 detection in adenocarcinomas.Arch Pathol Lab Med 1991;115: 886–890.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2000

Authors and Affiliations

  1. 1.Department of DermatologyUniversity of HeidelbergHeidelbergGermany
  2. 2.Department of Medicine, Division of GastroenterologyUniversity of HeidelbergHeidelbergGermany

Personalised recommendations